Skip to main content
. 2015 May 1;10(5):e0124951. doi: 10.1371/journal.pone.0124951

Fig 3. AMPK activation reduced SREBP-2 protein and target gene expression in the livers of AICAR-treated Tshr -/- and Tshr +/+ mice.

Fig 3

(A) SREBP-2 protein levels were decreased in Tshr -/- mice (n = 3 animals/group), Densitometric quantifications of SREBP-2 (P) and SREBP-2 (N) are shown. (B) HMGCR and HMGCS expression in the livers of Tshr -/- and Tshr +/+ mice. *p < 0.05 versus Tshr +/+ mice. (C) AMPK activation decreased the expression of the SREBP-2 precursor and nuclear forms in the livers of AICAR-treated Tshr -/- and Tshr +/+ mice. Tshr -/- and Tshr +/+ mice were injected intraperitoneally three times a week for 2 weeks with AICAR or PBS, and liver extracts were subjected to WB with antibodies against p-AMPK and SREBP-2. The WBs are representative of the 5 animals per group. (D-E) Densitometric quantifications of p-AMPK, SREBP-2 (P) and SREBP-2 (N). The data are presented as the mean ± SEM. *p< 0.05 versus PBS-treated Tshr +/+ mice, # p < 0.05 versus PBS-treated Tshr -/- mice. (F) HMGCR and HMGCS expression in the livers of AICAR-treated Tshr -/- and Tshr +/+ mice. The data are presented as the mean ± SEM. *p < 0.05 versus PBS-treated Tshr +/+ mice.